DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC

This study will evaluate the safety and efficacy of DEB-TACE with visualable embolization microspheres versus PVA microspheres for hepatocellular carcinoma.

Trial Details

NCT ID
NCT06190665
Phase
NA
Sponsor
Zhongda Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • DEB-TACE with visualable microspheres
  • DEB-TACE with PVA microspheres
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • CNLC Ia-IIIa HCC patients who require transarterial chemoembolization (TACE) and are not suitable for or refuse surgical resection, liver transplan…
  • ECOG PS score of 0-2
  • With measurable lesions that had not been embolized (if there are more than 3 lesions, select the three largest lesions as target lesions, and the …
  • Agree to participate in this trial and voluntarily sign the informed consent form

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →